液体活检在卵巢癌中的应用：循环 miRNA 和外泌体的潜力。

Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes.

机构信息

Department of Chemistry, Analysis of Circulating Tumor Cells lab, Lab of Analytical Chemistry, University of Athens, University Campus, Athens, Greece.

Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany.

出版信息

Transl Res. 2019 Mar;205:77-91. doi: 10.1016/j.trsl.2018.10.003. Epub 2018 Oct 12.

DOI:10.1016/j.trsl.2018.10.003

PMID:30391474

Abstract

Ovarian cancer still remains the most lethal female cancer, since in most cases it is diagnosed at an advanced stage. Usually after completion of primary treatment chemoresistance occurs, and recurrent disease is finally observed. Liquid biopsy, based on minimally invasive and serial blood tests, has the advantage of following tumor evolution in real time, offering novel insights on precision medicine. Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating cell-free microRNAs (cfmiRNAs) and circulating exosomes represent the major components of liquid biopsy analysis. Liquid biopsy has been already implemented in ovarian cancer, and most studies so far are mainly focused on CTCs and ctDNA. This review is mainly focused on the clinical potential of circulating miRNAs and exosomes as a source of liquid biopsy biomarkers in ovarian cancer diagnosis, prognosis, and response to treatment.

摘要

卵巢癌仍然是女性中最致命的癌症，因为大多数情况下，它在晚期才被诊断出来。通常在完成初始治疗后会发生化疗耐药，最终会观察到复发性疾病。基于微创和连续血液检测的液体活检具有实时跟踪肿瘤演变的优势，为精准医学提供新的见解。循环肿瘤细胞（CTCs）、循环肿瘤 DNA（ctDNA）、循环无细胞 microRNAs（cfmiRNAs）和循环外泌体是液体活检分析的主要组成部分。液体活检已经在卵巢癌中得到应用，迄今为止，大多数研究主要集中在 CTC 和 ctDNA 上。本综述主要关注循环 miRNAs 和外泌体作为卵巢癌诊断、预后和治疗反应液体活检生物标志物的临床潜力。